Sensyne Health welcomes Richard Pye to its Board as CFO and announces Michael Norris and Geoff Race joining the Board as Non-Executive Directors

– UK, Oxford –  Sensyne Health plc (LON: SENS), the British Clinical AI technology company, today announced the appointments to its Board of Directors of Richard Pye as CFO, while Michael Norris, former interim CFO, and Geoff Race joined also the Board as Non-Executive Directors, both effective on 26 February 2021.

Richard Pye was previously Chief Investment Officer of Sensyne Health.

“I am delighted to welcome Richard, Geoff, and Michael to the Board of Sensyne. I would like to thank Michael for his excellent service as Interim CFO and I am delighted he has agreed to stay with the business as a Non-Executive Director. These senior appointments, combined with our strong team, will help us boost commercial momentum and accelerate the scaling of the business internationally.” said Board Chairman, Sir Bruce Keogh. 

About Dr. Richard Pye

Dr. Richard Pye has over 15 years’ experience in corporate finance and investor relations in the public market life science sector. Before joining Sensyne, Richard was at Summit Therapeutics plc, an AIM and Nasdaq-listed biopharmaceutical company, where he held several leadership roles including most recently the position of VP of Corporate Affairs and Investor Relations. At Summit, he was involved in a wide range of corporate activities including financial reporting, cross-border capital raises, corporate development and strategy, investor communications, and corporate governance.

Richard holds a Ph.D. in organic chemistry and was a Post-Doctoral Research Associate at the University of Oxford before moving into the life sciences industry.

About Michael Norris

Michael Norris has served as Interim CFO at Sensyne Health since March 2020 and has more than 20 years of experience working with public and private companies in the technology and life sciences sectors. Michael is currently also Director and CFO of Beckley Psytech Ltd, a company developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. He has a wealth of CFO and Interim CFO experience having served in those roles for several companies in the UK and US.

Michael is a Fellow of the Chartered Institute of Management Accountants.

About Geoff Race

Geoff Race is the co-founder, EVP, CFO, and CBO of Nasdaq listed biopharmaceutical company Minerva Neurosciences Inc. He has more than 20 years of experience as CEO and CFO in the life science industry, including roles at Funxional Therapeutics Ltd, PanGenetics BV and CareX SA. Geoff is also a Non-Executive Director at Nasdaq listed F-star Therapeutics Inc. and Chairman and co-founder of London based consumer behavior data providers, Huq Industries Ltd.

Geoff received an MBA from Durham University Business School, UK, and is a Fellow of the Chartered Institute of Management Accountants.

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. This work uses data provided by patients and collected by the NHS as part of their care and support. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information: https://www.sensynehealth.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.